Reimbursement Changes To Further Burden Patients

BMI believes that proposed amendments to Hungary's reimbursement system will place substantial pressure on manufacturers of patented treatments and severely ill patients. Draft amendments to reimbursement levels for drugs included on the country's Positive List could see the removal of lower reimbursement limits for groups of medicines that treat serious diseases. The re-evaluation of reimbursement eligibility and co-payment requirements would be increased from twice per annum to six

To read the full article, please choose one of the following options: